Prostate Health [2026]: What Men Over 50 Should Actually Know

Prostate conditions — benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer — collectively affect the majority of men over 50, yet the evidence on screening, treatment, and when intervention is necessary is more contested and nuanced than most public health communication conveys. Here is the honest guide to prostate health based on current evidence.

Benign Prostatic Hyperplasia: The Most Common Condition

Benign prostatic hyperplasia (BPH) — non-cancerous enlargement of the prostate gland that gradually obstructs urinary flow — affects approximately 50% of men in their 50s and 90% of men in their 80s. Symptoms: urinary frequency (needing to urinate more often, especially at night), urinary urgency, weak or interrupted stream, feeling of incomplete emptying, and in severe cases urinary retention. BPH is not cancer and doesn't increase cancer risk, though both conditions can coexist. Mild symptoms often require only watchful waiting with lifestyle modifications (reduced evening fluid intake, caffeine reduction, regular voiding schedules). Medical treatment (alpha-blockers like tamsulosin, 5-alpha reductase inhibitors like finasteride) is effective for moderate symptoms. Surgical options are reserved for severe or medically refractory cases.

PSA Screening: The Contested Question

PSA (prostate-specific antigen) screening for prostate cancer has been one of medicine's most debated preventive interventions. The US Preventive Services Task Force currently recommends that men aged 55-69 discuss the decision with their physician, weighing individual values about the benefits (early detection of cancers that might become life-threatening) against the harms (false positives leading to unnecessary biopsies, overdiagnosis of slow-growing cancers that would never cause symptoms, treatment side effects including incontinence and erectile dysfunction). The USPSTF recommends against PSA screening for men 70 and older, where the benefit-harm balance is less favorable.

The nuanced reality: prostate cancer is extraordinarily heterogeneous. Some prostate cancers are slow-growing and unlikely to cause death in a man's lifetime — treating these cancers produces the side effects of treatment without meaningful benefit. Other prostate cancers are aggressive and life-threatening — detecting and treating these early produces genuine benefit. Current active surveillance protocols (monitoring low-risk cancers rather than immediately treating) have reduced overtreatment while catching the tumors that progress.

Honest Bottom Line: BPH affects 50% of men in their 50s and 90% by their 80s — mild symptoms are managed with lifestyle modification; moderate symptoms respond well to alpha-blockers or 5-ARIs; surgery is reserved for severe cases. PSA screening for men 55-69 is a shared decision with physician, weighing early detection benefits against false positives, overdiagnosis, and treatment side effects. Active surveillance (monitoring rather than immediately treating low-risk prostate cancer) has reduced overtreatment significantly — not all diagnosed prostate cancers require immediate intervention.